<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="794">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941485</url>
  </required_header>
  <id_info>
    <org_study_id>A01354</org_study_id>
    <nct_id>NCT01941485</nct_id>
  </id_info>
  <brief_title>WaveLight® Refractive Flap Accuracy Study</brief_title>
  <official_title>A Prospective, Global, Multi-Center Study to Evaluate Longitudinal Flap Accuracy on Subjects Undergoing Myopic Refractive Surgery Using the WaveLight® Refractive Suite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>Greece: Ethics Committee</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the accuracy of the WaveLight FS200 femtosecond
      laser, as assessed by 1 day and 1 month post-operative OCT anterior segment corneal
      measurements compared to pre-operative flap thickness target.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Difference Between Achieved Flap Thickness at Day 1 Postoperative as Assessed by OCT and Expected Flap Thickness as Determined Pre-operatively</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>The expected flap thickness as determined pre-operatively was subtracted from the achieved flap thickness at Day 1 postoperative as assessed by optical coherence tomography (ie, an imaging method using light to capture three-dimensional images).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opaque Bubble Layer (OBL) Development</measure>
    <time_frame>Day 0 (operative day)</time_frame>
    <safety_issue>No</safety_issue>
    <description>OBL (ie, a complication of corneal flap creation) assessed by digital photo analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Difference Between Achieved Flap Thickness at Month 1 Post-operative as Assessed by OCT and Expected Flap Thickness as Determined Preoperatively</measure>
    <time_frame>Month 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>The expected flap thickness as determined pre-operatively subtracted from the achieved flap thickness at Month 1 postoperative as assessed by optical coherence tomography (ie, an imaging method using light to capture three-dimensional images).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity (UCVA)</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual acuity (VA) without spectacles or other visual corrective devices, assessed a distance of 4 meters and measured in logMAR (logarithm of the minimum angle of resolution), with 0.00 logMAR corresponding to 20/20 Snellen. A lower logMAR value indicates better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA) at Distance</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>VA with the participant's best spectacles or other visual corrective devices assessed at a distance of 4 meters and measured in logMAR (logarithm of the minimum angle of resolution), with 0.00 logMAR corresponding to 20/20 Snellen. A lower logMAR value indicates better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manifest Refraction</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Manifest refraction as performed using visual acuity charts at a distance of 4 meters to document the sphere, cylinder and axis readings, measured in diopters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Acuity</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Contrast acuity (ie, a measurement of the ability to see between different shades of gray from the background) assessed in accordance with the manufacturer's guidelines, measured in logCS. A higher logCS value indicates better contrast acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Flap Diameter</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diameter of the corneal flap as assessed by OCT and measured in microns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wavefront Aberrometry</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Wavefront error of the eye as measured with a commercially available system and recorded in microns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Reported on RSVP Questionnaire</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Refractive Status and Vision Profile (RSVP) is a self-reported questionnaire used to measure vision-related health status in persons with refractive error.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Curvature as Measured by Keratometry</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Corneal curvature as assessed by a commercially available system and measured in diopters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flap Creation Time</measure>
    <time_frame>Day 0 (operative day)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Treatment time with Femtosecond FS200 laser, measured in seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Topography</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Corneal topography as assessed by a commercially available system.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>WaveLight Refractive Suite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LASIK surgery (laser in situ keratomileusis) per standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WaveLight® Refractive Suite</intervention_name>
    <description>Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation</description>
    <arm_group_label>WaveLight Refractive Suite</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LASIK surgery</intervention_name>
    <description>Surgical procedure for treating refractive error based on corneal reshaping</description>
    <arm_group_label>WaveLight Refractive Suite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to understand and sign an informed consent form.

          -  Have refractive error (in both eyes) that requires refractive surgery.

          -  Willing to undergo LASIK surgery using the Wavelight® Refractive Suite.

          -  Myopia between 0.00 to -12.0 Diopters pre-operatively.

          -  Astigmatism between 0.00 to +6.00 Diopters pre-operatively.

          -  Willing and able to attend post-operative examinations per protocol schedule.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Participation in a clinical study within the last 30 days.

          -  History of previous corneal surgery in either eye.

          -  Multifocal ablations in either eye.

          -  PRK or PTK surgery in either eye.

          -  Suffering from acute or recurring eye diseases in either eye, such as corneal ulcers,
             cataract, etc.

          -  Any ocular disease and/or condition that, in the Investigator's clinical judgment,
             may put subject at significant risk, compromise study results, or interfere
             significantly with subject's participation in the study.

          -  Unable to discontinue contact lens wear as specified in protocol.

          -  History of Herpes simplex or Herpes zoster keratitis.

          -  Active ocular rosacea.

          -  Lyme disease.

          -  Severe ocular allergies.

          -  Other medical conditions and use of medications as specified in protocol.

          -  Pregnant or planning to become pregnant during the study.

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefani Smith, MS</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 2, 2015</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <firstreceived_results_date>February 1, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nearsighted</keyword>
  <keyword>astigmatism</keyword>
  <keyword>LASIK</keyword>
  <keyword>refractive surgery</keyword>
  <keyword>WaveLight</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 1 study center located in the US and 1 study center located in Greece.</recruitment_details>
      <pre_assignment_details>Of the 60 enrolled participants, 1 was exited prior to surgery as a screen failure. This reporting group includes all enrolled participants who underwent LASIK surgery (59).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>WaveLight Refractive Suite</title>
          <description>Excimer EX500 and Femtosecond FS200 lasers used during LASIK surgery for corneal flap creation and corneal ablation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Trial Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>WaveLight Refractive Suite</title>
          <description>Excimer EX500 and Femtosecond FS200 lasers used during LASIK surgery for corneal flap creation and corneal ablation</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>18-29 Years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>30-39 Years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>40-49 Years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>≥ 50 Years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Difference Between Achieved Flap Thickness at Day 1 Postoperative as Assessed by OCT and Expected Flap Thickness as Determined Pre-operatively</title>
        <description>The expected flap thickness as determined pre-operatively was subtracted from the achieved flap thickness at Day 1 postoperative as assessed by optical coherence tomography (ie, an imaging method using light to capture three-dimensional images).</description>
        <time_frame>Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>This analysis population includes all participants who underwent LASIK surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>WaveLight Refractive Suite</title>
            <description>Excimer EX500 and Femtosecond FS200 lasers used during LASIK surgery for corneal flap creation and corneal ablation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Difference Between Achieved Flap Thickness at Day 1 Postoperative as Assessed by OCT and Expected Flap Thickness as Determined Pre-operatively</title>
            <description>The expected flap thickness as determined pre-operatively was subtracted from the achieved flap thickness at Day 1 postoperative as assessed by optical coherence tomography (ie, an imaging method using light to capture three-dimensional images).</description>
            <units>microns</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Right eye (OD)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.996" spread="12.7509"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Left eye (OS)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.644" spread="10.4762"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opaque Bubble Layer (OBL) Development</title>
        <description>OBL (ie, a complication of corneal flap creation) assessed by digital photo analysis.</description>
        <time_frame>Day 0 (operative day)</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Difference Between Achieved Flap Thickness at Month 1 Post-operative as Assessed by OCT and Expected Flap Thickness as Determined Preoperatively</title>
        <description>The expected flap thickness as determined pre-operatively subtracted from the achieved flap thickness at Month 1 postoperative as assessed by optical coherence tomography (ie, an imaging method using light to capture three-dimensional images).</description>
        <time_frame>Month 1</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uncorrected Visual Acuity (UCVA)</title>
        <description>Visual acuity (VA) without spectacles or other visual corrective devices, assessed a distance of 4 meters and measured in logMAR (logarithm of the minimum angle of resolution), with 0.00 logMAR corresponding to 20/20 Snellen. A lower logMAR value indicates better visual acuity.</description>
        <time_frame>Up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity (BCVA) at Distance</title>
        <description>VA with the participant's best spectacles or other visual corrective devices assessed at a distance of 4 meters and measured in logMAR (logarithm of the minimum angle of resolution), with 0.00 logMAR corresponding to 20/20 Snellen. A lower logMAR value indicates better visual acuity.</description>
        <time_frame>Up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Manifest Refraction</title>
        <description>Manifest refraction as performed using visual acuity charts at a distance of 4 meters to document the sphere, cylinder and axis readings, measured in diopters.</description>
        <time_frame>Up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast Acuity</title>
        <description>Contrast acuity (ie, a measurement of the ability to see between different shades of gray from the background) assessed in accordance with the manufacturer's guidelines, measured in logCS. A higher logCS value indicates better contrast acuity.</description>
        <time_frame>Up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Flap Diameter</title>
        <description>Diameter of the corneal flap as assessed by OCT and measured in microns.</description>
        <time_frame>Up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wavefront Aberrometry</title>
        <description>Wavefront error of the eye as measured with a commercially available system and recorded in microns.</description>
        <time_frame>Up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Reported on RSVP Questionnaire</title>
        <description>The Refractive Status and Vision Profile (RSVP) is a self-reported questionnaire used to measure vision-related health status in persons with refractive error.</description>
        <time_frame>Up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Curvature as Measured by Keratometry</title>
        <description>Corneal curvature as assessed by a commercially available system and measured in diopters.</description>
        <time_frame>Up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Flap Creation Time</title>
        <description>Treatment time with Femtosecond FS200 laser, measured in seconds.</description>
        <time_frame>Day 0 (operative day)</time_frame>
        <safety_issue>No</safety_issue>
        <population>This analysis population includes all participants who underwent LASIK surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>FS200 Laser</title>
            <description>Femtosecond FS200 laser used during LASIK surgery for corneal flap creation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Flap Creation Time</title>
            <description>Treatment time with Femtosecond FS200 laser, measured in seconds.</description>
            <units>seconds</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Right eye (OD)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34.864" spread="7.3001"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Left eye (OS)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.220" spread="7.7550"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Topography</title>
        <description>Corneal topography as assessed by a commercially available system.</description>
        <time_frame>Up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) reported from the time of enrollment to the Primary Completion Date, but data collection is ongoing and will be updated upon trial conclusion. This analysis population includes all enrolled participants.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the medical device.</desc>
      <group_list>
        <group group_id="E1">
          <title>WaveLight Refractive Suite</title>
          <description>Excimer EX500 and Femtosecond FS200 lasers used during LASIK surgery for corneal flap creation and corneal ablation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ravaughn Williams, Clinical Project Lead, GCRA</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
